The ability of a SARM to increase muscle mass may prove beneficial in postmenopausal women with stress urinary incontinence (SUI) where pelvic floor muscle weakness leads to unintentional loss of urine.
GTx is evaluating enobosarm in postmenopausal women with SUI in a Phase 2 proof-of-concept clinical trial. Data from the trial is expected during the first half of 2017, which will allow the Company to determine if continued development of enobosarm or another of our SARM compounds in SUI is warranted. More information about our clinical trials may be found here.
More information on Stress Urinary Incontinence may be found here.